Molecular Partners AG Sponsored ADR (MOLN)
(Delayed Data from NSDQ)
$4.69 USD
+0.07 (1.52%)
Updated Sep 26, 2024 02:05 PM ET
After-Market: $4.90 +0.21 (4.48%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Molecular Partners AG Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 208 | 261 | 145 | 185 | -99,999 |
Receivables | 2 | 1 | 28 | 3 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 4 | 5 | 6 | 1 | NA |
Total Current Assets | 214 | 267 | 180 | 190 | NA |
Net Property & Equipment | 6 | 8 | 9 | 10 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 0 | 0 | NA |
Total Assets | 221 | 275 | 189 | 200 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 1 | 2 | 8 | 6 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | NA |
Accrued Expenses | 8 | 8 | 11 | 8 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 5 | 7 | 31 | 46 | NA |
Total Current Liabilities | 16 | 18 | 51 | 62 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 6 | 6 | 15 | 18 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 24 | 28 | 72 | 86 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 4 | 4 | 4 | 3 | NA |
Capital Surplus | 407 | 378 | 388 | 319 | NA |
Retained Earnings | -214 | -134 | -275 | -208 | NA |
Other Equity | 0 | 0 | 0 | 0 | NA |
Treasury Stock | 1 | 1 | 0 | 0 | NA |
Total Shareholder's Equity | 197 | 246 | 117 | 114 | NA |
Total Liabilities & Shareholder's Equity | 221 | 275 | 189 | 200 | NA |
Total Common Equity | 197 | 246 | 117 | 114 | 0 |
Shares Outstanding | 36.30 | 36.00 | 32.20 | NA | NA |
Book Value Per Share | 5.41 | 6.85 | 3.65 | 0.00 | 0.00 |
Fiscal Year End for Molecular Partners AG Sponsored ADR falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 176 | 199 | 208 | 234 | 243 |
Receivables | 4 | 4 | 2 | 2 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 3 | 4 | 4 | 5 |
Total Current Assets | 183 | 206 | 214 | 240 | 249 |
Net Property & Equipment | 5 | 6 | 6 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 189 | 212 | 221 | 247 | 256 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 4 | 1 | 2 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 1 | 1 | 1 | 1 | 1 |
Accrued Expenses | 7 | 7 | 8 | 8 | 7 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 5 | 5 | 6 |
Total Current Liabilities | 13 | 14 | 16 | 16 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 6 | 5 | 6 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 17 | 20 | 24 | 25 | 27 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 4 | 4 | 4 | 4 | 4 |
Capital Surplus | 406 | 419 | 407 | 412 | 404 |
Retained Earnings | -237 | -229 | -214 | -193 | -178 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 1 | 1 | 1 | 1 |
Total Shareholder's Equity | 172 | 193 | 197 | 222 | 229 |
Total Liabilities & Shareholder's Equity | 189 | 212 | 221 | 247 | 256 |
Total Common Equity | 172 | 193 | 197 | 222 | 229 |
Shares Outstanding | 36.60 | 36.30 | 36.30 | 36.30 | 36.30 |
Book Value Per Share | 4.70 | 5.31 | 5.41 | 6.12 | 6.31 |